Human mesenchymal stem cells (hMSC) are a promising source for cell therapy after stroke. To deliver these cells, an IV injection appears safer than a local graft. We aimed to assess the whole-body biodistribution of IV-injected 99m Tc-HMPAO-labeled hMSC in normal rats (n = 9) and following a right middle cerebral artery occlusion (MCAo, n = 9). Whole-body nuclear imaging, isolated organ counting (at 2 and 20 h after injection) and histology were performed. A higher activity was observed in the right damaged hemisphere of the MCAo group [6.5 ± 0.9 × 10 −3 % of injected dose (ID)/g] than in the control group (3.6 ± 1.2 × 10
INTRODUCTION
plied later on after the stroke onset with the aim of enhancing brain plasticity (29, 41, 45, 53) . It has recently been shown that this could be achieved by cell trans-Stroke is the leading cause of acquired disability in adults in industrialized countries. Admission to special-plantation (8, (36) (37) (38) . Among various cell types, human mesenchymal stem ized stroke units (25, 52) and thrombolysis (43,54) are the only effective strategies for the early treatment of cells (hMSC), derived from bone marrow, offer the advantage of not originating from a tumoral or modified acute ischemic stroke. Unfortunately, the brief time window limits thrombolysis to a small fraction of patients. source (28) . Moreover, they are poorly immunogenic (1,34,48) and do not lead to the ethical problems associ-Thus, an alternative strategy is needed that could be ap-1370 DETANTE ET AL. ated with embryonic stem cells. The use of hMSC for been performed in various pathological conditions such as chronic paraplegia (18) and myocardial infarction cell therapy relies on their capacity to graft and survive for a long time in the tissue of interest (12). Bone mar-(5,32). Briefly, radiolabeled MSC were mainly detected in the lungs, liver, kidney, infarcted myocardium, and row-derived hMSC are identified as multipotent progenitor cells that differentiate both into mesenchymal and spleen following IV injection. A recent human case report used bone marrow mononuclear cells radiolabeled nonmesenchymal lineages, including neurons and endothelia (56) . As such, MSC promote structural and func-with 99m Tc (17) . Nine days after ischemic stroke, these cells were injected intra-arterially. Twenty-four hours tional repair in several organs, notably in the brain after stroke in rodent models using either the intracerebral later, the labeled cells were observed, using in vivo nuclear imaging, in the damaged brain, liver, and spleen (10,14, 35) , intra-arterial (50) , or intravenous (IV) (13, 15, 34, 39, 46, 51, 57) administration. Despite a potential (17) . To our knowledge, no study assess the biodistribution of IV-injected radiolabeled hMSC after stroke. better efficiency of local delivery (intracerebral route), systemic IV administration appears to be safer and eas-These data are however necessary to evaluate the risk of a systemic cell therapy after stroke and/or its therapeutic ier than local brain grafting following stroke in the clinical setting as it is less invasive. Intracerebral delivery is potential, quantifying the hMSC homing to the ischemic lesion. limited to small graft sites into large ischemic lesions whereas IV injection allows cell distribution into vascu-Thus, the aim of our study was to evaluate the wholebody biodistribution of 99m Tc-HMPAO-labeled hMSC larized and viable areas of the lesion. In humans, the first clinical trial demonstrated that IV delivery of following IV injection in normal rats and in rats subjected to focal cerebral ischemia. hMSC is feasible and safe after stroke (4).
In experimental studies showing a benefit of hMSC MATERIALS AND METHODS administration following stroke, there are little data reported about the quantity of hMSC localizing in the All animal procedures conformed strictly to French government guidelines for the use and care of animals brain lesion and about cell redistribution and/or elimination from other organs. MSC imaging can provide such (license #380806 for O. Detante). Surgical procedures were conducted under aseptic conditions and every ef-data. MSCs have previously been labeled with paramagnetic particles for magnetic resonance imaging (MRI) fort was made to reduce animal suffering. Anesthesia was induced by inhalation of 5% isoflurane (Forène, Ab-(23) and organs of interest such as the kidneys, liver (21, 26) , heart (22, 32) , or brain (27, 30) have been studied bott Laboratory) in 30% O 2 in air and maintained throughout all surgical and imaging procedures with 2-in vivo. Unfortunately, MRI has a poor sensitivity and whole-body cell MRI is challenging in experimental 2.5% isoflurane through a facial mask. conditions.
hMSC Labeling hMSC radioactive labeling (7) and nuclear imaging are better suited for whole-body biodistribution studies.
The hMSC were isolated from bone marrow aspirate from a healthy donor who gave informed consent. Isola-Because of its short decay time (6 h) and its emission energy well adapted to gamma-cameras, thus ensuring tion and culture procedures were conducted in the Cell Therapy Unit (biotherapy team of general clinical re-high image quality, 99m Tc is better suited than 111 In for short tracking of hMSC in vivo (2,6). 99m Tc is a radioac-search centre, University Hospital of Grenoble), in accordance with good laboratory practices. Cell cultures tive agent widely used in clinical practice for scintigraphy in nuclear medicine. Technetium 99m-hexamethyl-were performed according to previously described methods (42, 48) . propylene amine oxime ( 99m Tc-HMPAO) is a lipophilic complex that is reduced into a hydrophilic complex by For each experiment, approximately 7 × 10 6 hMSC were incubated for 15 min in 370 MBq of 99m Tc-a glutathione-dependent mechanism after trapping into the cell (44) . It provides a stable labeling for in vivo cell HMPAO prepared according to the instructions of the manufacturer (Ceretec, GE Healthcare). The prepara-tracking, and many cell types have already been labeled with 99m Tc-HMPAO to study cell biodistribution over tion was used within 30 min after reconstitution, as recommended (47) . Cells were rinsed twice and resus-periods of up to 24 h. In unconditioned mice, Allers et al.
(3) mainly observed lung, liver, and spleen activity pended in 1 ml of phosphate-buffered saline (PBS) prior to IV injection. These labeling conditions were chosen 24 h after IV injection of hMSC labeled with 99m Tc-HMPAO. Gao et al. (19) confirmed these results in according to preliminary in vitro assays (data not shown). Flow cytometry was used to check radiolabeled healthy rats after IV injection of 111 In-labeled MSC. The authors observed an early lung activity, which redistrib-cell viability using 7-amino-actinomycin D (7-AAD, BD PharMingen) at 24 and 48 h after labeling. Colony form-uted in the liver, kidneys, spleen, and long bones 48 h after injection. Nuclear cell imaging studies have also ing unit fibroblast (CFU-F) assay was also performed to evaluate the in vitro proliferation capacity of the labeled Whole-Body Nuclear Imaging hMSC.
Immediately after radiolabeled hMSC injection, the rats were installed in a cradle. The cradle was placed Animal Model and Experimental Groups vertically in front of a dual-head small-animal gammacamera (gamma-imager, Biospace Lab, Paris, France). Eighteen adult Sprague-Dawley rats (Janvier, France) weighing between 250 and 300 g were randomly allo-
The two detectors were asymmetrically positioned so that scintigraphic image acquisition of the upper and cated into two groups: 1) a group that underwent a transient right middle cerebral artery occlusion (MCAo) lower halves of the animal body could be simultaneously performed by each detector, respectively. Gamma-(n = 9); 2) an age-matched control group without cerebral ischemia (n = 9). acquisition software (Biospace Lab) was used for image acquisition. The energy window for 99m Tc was 122-170 To perform the MCAo, rectal temperature was maintained at 37.0 ± 0.5°C with a feedback-controlled heat-keV, and decay correction was automatically applied to image counts recorded in the list mode. Image acquisi-ing electrical blanket connected to a rectal probe. Focal brain ischemia was induced by intraluminal occlusion of tion lasted for 120 min and began immediately following 99m Tc-hMSC injection in all nine control and nine the right MCA (40) . Briefly, the right carotid arterial tree was isolated. A cylinder of melted adhesive (length MCAo animals (initial imaging). A second, 120-min acquisition was initiated 18 h following the IV injection in 2 mm, diameter 0.38 mm) attached to a nylon thread (diameter 0.22 mm) was advanced from the lumen of four control and four MCAo rats (late imaging). These animals were awakened between imaging sessions. the external carotid artery into the internal carotid artery up to 5 mm after the external skull base. The rats were awakened and tested for spontaneous circling and fore-Biodistribution by Isolated Organ Counts limb flexion during the occlusion period. After 90 min, Immediately following completion of the initial scinrats were reanesthetized and the thread was removed.
tigraphic image acquisition (i.e., 120 min after 99m Tc-hMSC injection), five control and five MCAo rats were Brain MRI euthanized using a lethal dose of pentobarbital by intracardiac injection under isoflurane anesthesia. The eutha-MRI (7 T horizontal magnet) was performed to measure the ischemic lesion volume with a T 2 spin echo nasia of the remaining four control and four MCAo rats was performed immediately following the late image ac-weighted imaging (T 2 WI) (TR/TE = 2500/60 ms, field of view = 30 mm, thickness = 1 mm, matrix = 128 × 128, quisition (20 h after injection). Following euthanasia, samples from the left and right cerebral hemisphere, two averages) in five rats, 1-3 days after MCAo. Rectal temperature was maintained at 37.0 ± 0.5°C with a feed-heart, thyroid, salivary gland, stomach, liver, spleen, kidney, lung, and skeletal (hind limb) muscle were quickly back-controlled heating water blanket. The whole ischemic lesion was manually delineated on each slice. Le-obtained, rinsed in physiological saline, and weighed. Samples of blood and urine were also collected. 99m Tc-sion volumes were computed by multiplying the number of pixels by pixel surface area and slice thickness.To hMSC activity was assessed using a gamma-well counter (Cobra II, Packard Instruments) with a 120-160 assess blood-brain barrier permeability 1 week after MCAo, T 2 WI and T 1 WI (same spatial resolution) before keV 99m Tc energy window. All tissue counts were corrected for background and decay during the time of and after an IV injection of gadolinium were performed in four additional rats.
counting.
Histology Intravenous Injection of hMSC 99m
Tc-hMSC (in 1 ml of PBS) were injected as a slow Samples of lung, spleen, liver, and brain were obtained prior to gamma-well counting from both groups. bolus into the saphenous vein. One week after cerebral ischemia, the MCAo group received an injection of They were stored at −80°C and cut using a cryostat into 20-µm sections. Transplanted hMSC were identified 3.4 ± 1.2 × 10 6 cells (corresponding to an injected activity of 78.8 ± 35.1 MBq). The control group received with a human-specific monoclonal antibody to nuclear antigen (MAB1281; 1/2000; Chemicon, CA, USA). This an injection of 3.2 ± 1.1 × 10 6 cells (76.4 ± 24.7 MBq). The injected dose was within the effective therapeutic primary antibody was incubated overnight at 4°C. A fluorescent anti-mouse secondary antibody (1/500; Jackson dose range for IV grafts (15, 34, 51) .To assess the biodistribution of 99m Tc-HMPAO alone, 99m Tc-HMPAO (81.1 ± laboratory, MA, USA) was then applied for 1 h. All cell nuclei were counterstained blue with Hoechst prior to 3.6 MBq) alone was injected in four additional rats, 1 week after a right MCAo.No immunosuppressive agents examination under epifluorescent microscopy (Nikon Eclipse E600, Japan). Prior to this study, the histological were used in agreement with previous studies (16, 34) . methodology was set up on brains that had received an Cerebral Lesion Size by MRI intracerebral hMSC grafts after stroke.
All rats in MCAo group, awakened over the course of the artery occlusion period (90 min), exhibited neuro-Data Analysis logical deficits as a consequence of the ongoing cerebral ischemia. The control rats had no deficit. In addition, Image Analysis. Gamma-vision + software (Biospace the cerebral lesion (infarcted tissue and edema) was au-Lab, Paris, France) was used for examiner-blind analysis thenticated by MRI, 1-3 days following MCAo. Mean of planar images. Regions of interest (ROI) were drawn volume was 262.5 ± 193.7 mm 3 .The four additional rats on the whole brain, lung, and both left and right kidneys.
that were submitted to MCAo and received gadolinium No ROI was drawn on the liver because of possible lung 1 week later exhibited lesion with a markedly increased superimposition. ROI activities were expressed as counts blood-brain barrier permeability. per minute per mm (cpm/mm 2 ). Eighteen-hour decay correction was applied to the ROI quantifications that
Whole-Body Nuclear Imaging were performed on late images. Initial and late ROI ac-Immediately after labeling, 99m Tc-HMPAO-labeled tivities were then normalized towards the injected dose hMSC were injected in rats. Each group received the expressed as GBq and therefore expressed as cpm/mm 2 / same number of cells (3.4 ± 1.2 × 10 6 cells for the GBq.
MCAo group; 3.2 ± 1.1 × 10 6 cells for control group) Biodistribution Analysis. Organ, blood, and urine acand the same injected radioactivity (78.8 ± 35.1 MBq tivities of 99m Tc-hMSC were expressed as cpm, decayfor MCAo group; 76.4 ± 24.7 MBq for control group). corrected to the time of injection, and normalized to the Images in Figure 1 were obtained from most representatissue weight (g) and to the injected dose also expressed tive rats in each group and are given as an example. as cpm. For the purpose of clarity, these results, initially Table 1 shows quantitative imaging data (corrected for expressed as percent of the injected dose per gram of decay) useful for result comparison. sample weight (%ID/g), were finally expressed as 10 −3 A trend towards higher activity in the whole brain %ID/g. following ischemia was observed in the MCAo group (23.3 ± 3.5 cpm/mm 2 /GBq at 2 h and 8.7 ± 1.8 cpm/ Statistical Analysis mm 2 /GBq at 20 h) when compared with control rats All results are expressed as mean ± SD. Between-(20.3 ± 3.5 cpm/mm 2 /GBq at 2 h and 7.9 ± 2.1 cpm/ group comparison of mean values was performed using mm 2 /GBq at 20 h). the unpaired Student t-test after checking the homogene-An early and significant lung trapping was observed in ity of variance (Levene's test). Paired t-test was used for all rats as indicated by the initially high pulmonary activwithin-group comparison (left vs. right hemisphere). A ity. This phenomenon was transient as the lung activity value of p < 0.05 was considered as significant.
decreased dramatically between the initial and late imaging sessions (control group, from 2209.9 ± 487.2 to 153.5 ± RESULTS 75.8 cpm/mm 2 /GBq; MCAo group, from 2749.2 ± 544.6 hMSC Labeling to 231.3 ± 39.6 cpm/mm 2 /GBq). Cultured hMSC expressed CD73, CD90, and CD105
Finally, the route of 99m Tc-hMSC elimination was but were CD45 − and CD34 − (data not shown). These mostly renal as shown from in vivo planar images. Kidcells differentiate into osteoblasts, chondrocytes, and adney radioactivity was stable over time. No significant ipocytes as previously described (42) .
difference was observed between the MCAo and control The efficiency of 99m Tc-HMPAO hMSC labeling (i.e.,
groups. percentage of radiotracer activity incorporated into cells
Concerning whole-body quantification, we observed over the total activity of radiotracer mixed with cells) that, at 20 h, 27.6 ± 6.6% and 29.5 ± 7% of the 2-h acwas 26.7 ± 11.6%. In vitro assays showed that more tivities are still visualized for control and MCAo groups, than 96% of the initial 99m Tc activity remained into viarespectively. ble hMSC 4 h after labeling.
Biodistribution by Isolated Organ Counts Using flow cytometry with 7-AAD, we observed that the 99m Tc-HMPAO-labeled hMSC viability was 97.9%
At 2 h following 99m Tc-hMSC injection, the right damaged hemisphere activity in MCAo rats tended to be and 96.1%, respectively, at 24 and 48 h after labeling (compared to ϳ98% viability of unlabeled cells). Cells higher than in controls (11.6 ± 2.8 × 10 −3 %ID/g vs. 7.9 ± 2.5 × 10 −3 %ID/g; p = 0.059). A marked difference ap-were also cultured to evaluate their capacity to form colonies. After 10 days of cell culture, no colony was de-peared 20 h after injection (6.5 ± 0.9 × 10 −3 %ID/g vs. 3.6 ± 1.2 × 10 −3 %ID/g; p = 0.010). One out of 10,000 tected for 99m Tc-HMPAO-labeled hMSC whereas 29% of unlabeled hMSC were able to form colony. injected 99m Tc-hMSC migrated to the right damaged hemisphere of MCAo rats. This proportion was half of One week after MCAo, IV injection of 99m Tc-HMPAO alone led to higher activity into the left normal this in the control rats. Moreover, the late contralateral hemisphere activity was significantly higher in the hemisphere than in the right damaged one, 2 and 20 h after injection (mean activity right/left hemisphere: MCAo group when compared with the control group (Table 2) . Within the MCAo group, the initial ipsilateral 0.93 ± 0.02 and 0.89 ± 0.10, respectively), despite an altered blood-brain barrier in the lesion. hemisphere activity was significantly higher than the contralateral one (11.6 ± 2.8 × 10 −3 %ID/g vs. 9.8 ± 1.7 ×
The organ counts indicated that hMSC could colonize an ischemic lesion in the brain after a systemic injection 10 −3 %ID/g, p = 0.024) (Fig. 2) . A comparison between control and middle cerebral artery occlusion (MCAo) groups was performed (unpaired t-test). Tracer activity was assessed 2 or 20 h following 99m Tc-hMSC systemic injection and is expressed as percentage of the injected dose per gram of organ (10 −3 %ID/ g): mean ± SD. All tissue counts were corrected for background and decay. Both right (damaged) and left hemisphere were counted for the MCAo group whereas whole brain activity was assessed for the control group. Percent change was calculated per group from mean values obtained across the five animals that were sacrificed at 2 h and across the four that were sacrificed at 20 h after injection. ns, no significant difference.
despite initial cell entrapment in the lungs. Lung trap-11,578.6 ± 11,552.6 × 10 −3 %ID/g to 485.5 ± 241.6 × 10 −3 %ID/g). The IV injection of 99m Tc-HMPAO alone ping was observed on in vivo images and was confirmed by the isolated organ count. Delayed hMSC redistribu-after MCAo led to a much smaller lung activity at both observation time points (2,340.7 ± 180.7 × 10 −3 %ID/g tion then occurred as observed following isolated lung counts in both groups (control group, from 18,696.0 ± at 2 h after injection and 1,213.9 ± 468.1 × 10 −3 %ID/g at 20 h). 14,675.6 × 10 −3 %ID/g at 2 h after injection to 1,181.7 ± 862.7 × 10 −3 %ID/g at 20 h; MCAo group, from Isolated organ counts also confirmed that the kidneys Figure 2 . Cerebral distribution of IV injected 99m Tc-hMSC after ischemic lesion shown by gammawell counting. A within-group comparison (paired t-test, MCAo group) showed a higher activity in the right (R) damaged hemisphere than in the left (L) one (p = 0.024 at 2 h; p = 0.070 at 20 h following hMSC injection). Tracer activity is expressed as percent of the injected dose per gram of organ (10 −3 %ID/g): mean ± SD.
were predominantly involved in the elimination of 99m Tc-Histology hMSC as indicated by the high renal and urinary activity.
Epifluorescence microscopy images suggested the presence of human cells in lungs, liver, spleen, and brain Finally, activity in the spleen increased significantly from 2 to 20 h after injection. Such an increase was in (damaged and contralateral hemispheres for MCAo group, and control brain only 20 h following hMSC in-contrast with the overall activity decrease observed in all other evaluated organs. These data suggested that hMSC jection) (Fig. 3) . No human nuclei were observed in the brain of control rats 2 h following hMSC IV injection. could be sequestered in the spleen.
We did not observe any correlation between the cere-Technical difficulties to obtain histological data from fragile samples as lungs or damaged brain did not allow bral lesion size and the cellular uptake in the different organs.
a histological cell quantification. Figure 3 . Histology. hMSC were identified as green with a human-specific monoclonal antibody (MAB1281). All cell nuclei were counterstained blue with Hoechst medium. Epifluorescence microscopy merged images showed human cells in lungs, liver, spleen, and brain (in the damaged right hemisphere and the contralateral for MCAo group, and in control brain 20 h following systemic injection of hMSC). No human cells were observed in brains of the control group 2 h after injection. R, right; L, left; MCAo, middle cerebral artery occlusion. Scale bar: 50 µm.
DISCUSSION
Imaging was not able to detect this difference due to a lack of sensitivity. These data about hMSC distribution Our aim was to evaluate the whole-body biodistribuare in accordance with previously published experimention of IV-injected hMSC after cerebral ischemia. Our tal studies that showed the benefit of IV injected MSC results indicate that: 1) some hMSC seems to be able to and the survival of grafted cells in the ischemic lesion migrate towards an ischemic brain lesion after a sysby histology (13, 15, 16, 57) . However, we presently temic injection despite the initial cell entrapment in the showed that only few injected hMSC are observed in lungs; 2) after 20 h, more hMSC are found in the ischethe brain (1/10,000 in the ischemic hemisphere corremic lesion than into the undamaged cerebral tissue; 3) sponding to 300 cells/3 × 10 6 injected hMSC). This pro-hMSC can be sequestered in the spleen and are predomiportion corresponds to previous histological results that nantly eliminated by kidneys; 4) planar nuclear imaging showed a poor graft survival in ischemic brain lesion (1 does not reach the sensitivity of gamma-well counting to 4/10,000) 4 days after IV injection of bone marrowto study the biodistribution of 99m Tc-HMPAO-labeled derived CD133 + cells (9). By histology, Li et al. (34) hMSC.
observed that 4% of 3 × 10 6 hMSC injected intrave-Cell Labeling and Viability nously 24 h after stroke entered the rat brain. In the present study, hMSC were delivered 1 week after stroke 111 In labeling of hMSC at a dose of 30 Bq/cell does and a lower fraction of the injected hMSC was found not induce cell adverse effects (7), whereas radiationinto the brain. The optimal time of transplantation deinduced cell damage was observed using 111 In labeling pends on the desired effect: acute neuroprotection or of hematopoietic progenitor cells (11). In our experineuroregeneration in a stabilized lesion (20) . Acute ment, 99m Tc labeling (5 Bq/cell) induces a loss of hMSC hMSC injection after stroke could induce the migration ability to form colonies. In vitro, no deleterious effect of a bigger number of cells into the damaged tissue. Inon cell proliferation was observed with HMPAO alone deed, most of the chemoattractant agent levels (as cytoand loss of hMSC proliferation seems to be due to the kines, chemokines, adhesion molecules) are elevated radioactive agent ( 99m Tc) (data not shown). However, our during the first days poststroke and return to baseline in results of flow cytometry with 7-AAD demonstrate a 1 week (20, 58) . However, an early hMSC injection after good cell viability over the experimental period (2 days).
stroke is not possible in clinical trials in case of autolo-The alteration of the ability of radiolabeled hMSC to gous transplantation (culture delay) (4). Our study sugproliferate must be carefully considered as it may alter gests that, 1 week after stroke, hMSC migrated towards their therapeutic benefit. For future experiments, espethe ischemic brain lesion. cially if related to long-term follow-up as is possible
Concerning the whole-body biodistribution, the when using 111 In labeling, only a small fraction of hMSC homing in nontarget organs such as the spleen grafted cells must therefore be radiolabeled and used to that was observed in the present study as well as in othtrack the rest of the unlabeled cell population (17) . ers must be carefully considered following either IV IV-Injected hMSC Are Attracted to Cerebral (3,19,32) or intra-arterial injection (17) .
Ischemic Lesion
Graft Route The apparent hMSC biodistribution within the brain following injection might be due to the release and bio-After IV administration of hMSC, transient early lung trapping was observed in the present study without distribution of the 99m Tc-HMPAO. To control this point, we injected 99m Tc-HMPAO alone in rats submitted to any obvious respiratory problem. Lung activity then decreased dramatically from 2 to 20 h after injection, sug-MCAo 1 week earlier. Despite an increased blood-brain barrier permeability (observed by MRI), we observed a gesting the migration of cells across the lung capillary network. No lung trapping was observed after IV injec-higher activity in the left normal hemisphere than in the damaged right, 2 and 20 h after injection (mean activity tion of 99m Tc-HMPAO alone. The phenomenon of lung trapping was previously observed in normal rats follow-right/left hemisphere = 0.93 ± 0.02 and 0.89 ± 0.10, respectively). The opposite ratios were observed after in-ing IV injection of 111 In-labeled MSC, which were detected initially in the lungs and later on in the liver and jection of labeled hMSC (MCAo group: 1.18 ± 0.09 and 1.16 ± 0.10) (Fig. 2) . These results suggest that a cell other organs (19) . MSC lung clearance increased following vasodilatation with sodium nitroprusside (19) . MSC release of 99m Tc-HMPAO would yield an underestimation of the amount of hMSC into the right damaged redistribution from the lungs to nontarget organs (liver, kidney, spleen) and to infarcted myocardium was also hemisphere.
Together with isolated brain counting and histology, observed following IV injection in a canine model (32). All these results suggest transient vascular lung trapping our results suggest that brain hemispheres, especially the damaged one, may attract viable hMSC following stroke.
rather than specific MSC homing in the pulmonary tis- used despite the initial lung accumulation, which can be reduced using a vasodilatator. REFERENCES Other graft routes, such as intra-arterial (50) or intra-
